New shot fights stomach cancer spread in early trial
NCT ID NCT07658196
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This early-phase trial tests a drug called ACM-CpG, given as an injection into the abdomen, for people with colorectal or appendix cancer that has spread to the lining of the belly or caused fluid buildup. The main goal is to find a safe dose and see if it helps control the disease. Up to 24 adults will receive the treatment and be closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APPENDICEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rhode Island and the Miriam Hospitals (Brown University Health)
Providence, Rhode Island, 02903/02906, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACM-CpG
What this could lead to
If this works, it could point toward a new treatment option for cancer that has spread to the lining of the abdomen, potentially helping control the disease.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, so it is primarily testing safety. The treatment may not shrink tumors or improve survival, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.